Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. - Wikidata - wikimedia - TriplyDB

Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways.

Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways.

http://www.wikidata.org/entity/Q44552007

about

P1343

Optimizing treatments for lymphangioleiomyomatosis Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models Management of lymphangioleiomyomatosis Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development.Gender, Estrogen, and Obliterative Lesions in the Lung.Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.Lymphangioleiomyomatosis and TSC2-/- cells Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.mTOR signaling in lymphangioleiomyomatosis Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor.Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis Sporadic lymphangioleiomyomatosis with bloody sputum as an initial symptom: A case report and review of the literature Overexpression of estrogen receptor beta is a prognostic marker in non-small cell lung cancer: a meta-analysis Lymphangioleiomyomatosis: what do we know and what are we looking for?Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans Lymphangioleiomyomatosis - a wolf in sheep's clothing.Lymphangioleiomyomatosis: current and future.Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells.

P2860

Q54604343-081BC8C7-05AB-48D5-AFD0-F1CCAC351F2D

P1343

Q26865250-8765417B-78C9-4BE0-8DD7-0C093F048002 Q27301399-6EF3F050-61D0-4D5A-A933-1F0B43907D56 Q27687650-DCD0C8CD-03F3-45EE-BDBE-1CAF0E4D680D Q28084725-F3D76EDC-4BB9-49A4-81F1-63C695B949CB Q28084975-C31A6BBC-48C0-411B-A305-B9122B68EA25 Q28392724-50CBA121-F735-4359-910A-C80DB3BFA9FC Q28728348-AAC828E4-0B5A-44FA-9C58-CC3DD376A31A Q28751693-26D6DC03-355B-467C-A449-36AA2AD357DB Q30411083-1F47941F-9074-4A85-9448-59D0C0C7D697 Q33528959-00E549E7-F368-4654-93B2-B2F609E328C5 Q33559661-C6B3B53A-1C37-4881-91EE-C7C6AE975FB1 Q33567156-0DF7230A-248F-4BD2-ADA2-7C659E5AF83B Q33658836-4F442E5A-1962-4040-84BB-6CD5A0F7E686 Q33720145-B716CC2F-0129-43E9-907B-AC17DD43576C Q33829595-06FCC2F7-D09D-494A-8587-8F76032D7DAE Q33904951-1963025A-C7B5-4787-8616-59A0779B39FC Q33905175-E473C9BB-1BEC-4F24-8E27-7841CD510E2A Q33905253-5B40B03D-3035-4CD1-A4FE-AEC77F5DE7E8 Q34167429-4A8A4FF1-E32A-423D-884B-5EE785302023 Q34199557-1B6E1072-E25D-408D-929C-B57990E9D478 Q34204852-0A1A0BC5-A7C2-46B7-886E-442F768846D3 Q34408059-9D4E1259-A844-444F-97AB-147F28ACA854 Q34652936-3626F057-7691-4AF8-B36E-7169BC8AB3C2 Q34924914-4CB51469-9468-4749-8DAB-B3F7DA5821A1 Q35033593-E519313F-56FF-4BCA-87A8-A48A66E78ADD Q35085208-FE97B7E9-6D1B-4246-987D-5307E4277F90 Q35610828-F1F5868D-7CF3-4703-8B2B-EEF6E6355767 Q35758056-B0FFA1E0-EB4B-42A5-9789-7A8908441D68 Q35958787-05EBBBD4-F3BA-47D6-848C-FB87D94CCF08 Q36067383-8D356DFE-1243-4D90-B3E7-E2BA36BC005A Q36291973-31AEA409-2680-4FE9-BB95-01EE593C8B2F Q36309469-96A4B378-A242-40F1-9361-99D55400217F Q36330644-1085820B-B129-4054-9CDD-81A3929B2AA3 Q36357766-9A243C34-C638-4BB7-AE50-B8532DA86668 Q36542254-BB145FCD-2668-418C-B5B8-654E41788DB5 Q36636671-47DC423C-78E4-435C-9DE4-125199C0E3BF Q37038637-89958F2D-000F-4D78-899D-0A912A1EF45C Q37056468-044E67E7-3D62-40A6-8F51-1CCBBF7A758D Q37057152-171D35C8-3C79-47DB-B8C2-FC805F74A559 Q37087123-75C2FC98-4790-4AFD-9211-70BC036AC014

P2860

Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways.

http://www.wikidata.org/entity/Q44552007

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Estradiol and tamoxifen stimul ...... nongenomic signaling pathways.

@en

Estradiol and tamoxifen stimul ...... nongenomic signaling pathways.

@nl

type

label

Estradiol and tamoxifen stimul ...... nongenomic signaling pathways.

@en

Estradiol and tamoxifen stimul ...... nongenomic signaling pathways.

@nl

prefLabel

Estradiol and tamoxifen stimul ...... nongenomic signaling pathways.

@en

Estradiol and tamoxifen stimul ...... nongenomic signaling pathways.

@nl

P1433

Q44552007-84026A22-BBC2-4567-A398-F96C7840C9A2

P1476

Q44552007-728AD8C3-6ECD-4C13-AF6E-B3BE3B930446

P2093

Q44552007-03FF5C9D-06EA-4996-9F54-F1482CFAE00B

Q44552007-5E37F527-3A33-4B19-94C9-AAE3F2C22E7E

Q44552007-E4DB860D-7875-4428-A2C5-40EF785CE0C0

P2860

Q44552007-07112FC1-1958-4410-9D13-E6531020AA3E

Q44552007-08215D3F-B62A-458E-BD46-BC2B8A11FA76

Q44552007-0966049C-4479-4D34-AB68-449B1277FF2D

Q44552007-0B27A6F4-4AF7-4965-8EED-485CC0EC8AD5

Q44552007-10D8A160-22CF-4778-9612-CAB6EDA4590A

Q44552007-1C68F6DC-E80B-4435-A99C-4926289DB517

Q44552007-1CBE1119-81B7-49F9-91E2-A0E89BBFC124

Q44552007-273FAC57-1745-4851-83D0-14D231C78B3A

Q44552007-27990693-3D89-43BF-BF8B-605A950306F1

Q44552007-2A8A9787-8084-4036-95B2-DA25138EE6F6

P304

Q44552007-59BD5B4F-B546-4BF5-8BAA-97AB1C486A21

P31

Q44552007-57973BFE-73D3-4099-8EF1-A405139641AE

P356

Q44552007-E4C1863E-A153-4E00-9DF5-DEFFB693B55C

P433

Q44552007-469714C0-CDA9-4F16-A460-897D606B32F6

P4510

Q44552007-95C81271-464C-42BE-93F7-F1FBD3A9B066

P478

Q44552007-C96A7DD7-6D09-4F20-959E-E15E8B013F8B

P50

Q44552007-85F3A3B5-0E1C-46ED-91EC-7CB639F93D9C

P577

Q44552007-1911CCBE-A9D8-4520-8947-47AC053FD2EC

P5875

Q44552007-52C7484C-E5FC-415A-870C-42C65DE08A78

P698

Q44552007-DF423146-69F8-4211-99BA-C4268E5E6F64

P921

Q44552007-2A8EA4C3-2930-48EE-AD19-71A165461C63

P356

AJPLUNG.00204.2003

P1433

American Journal of Physiology - Lung Cellular and Molecular Physiology

P1476

Estradiol and tamoxifen stimul ...... nongenomic signaling pathways.

@en

P2093

Elizabeth Petri Henske

http://www.w3.org/2001/XMLSchema#string

Jane Yu

http://www.w3.org/2001/XMLSchema#string

Sharon Howard

http://www.w3.org/2001/XMLSchema#string

P2860

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

The TSC1 gene product, hamartin, negatively regulates cell proliferation

The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3

Identification and characterization of the interaction between tuberin and 14-3-3zeta

The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis

Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells

TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

P304

L694-700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPLUNG.00204.2003

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P4510

P478

286

http://www.w3.org/2001/XMLSchema#string

P50

Aristotelis Astrinidis

P577

2003-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10610150

http://www.w3.org/2001/XMLSchema#string

P698

12922981

http://www.w3.org/2001/XMLSchema#string

P921